Tag: Radiopharmaceuticals

Radiopharmaceuticals and Data Integrity

Today the nuclear medicine is an advanced way of oncologic, neurologic and cardiac diseases diagnosis and treatment, while the nuclear medicine development is impossible without radiopharmaceuticals. ...

Overview of GMP Requirements for Radiopharmaceuticals

The new WHO and IAEA guidelines are intended to provide a general overview of GMP (Good Manufacturing Practice) requirements for radiopharmaceuticals. While the basics of GMP are presented in the gene...

Russian researchers to develop new cancer drug

cancer-test
Russian researchers announced the development of a combined action drug based on ionizing radiation and bacterial toxin.

Telix Pharmaceuticals buys Advanced Nuclear Medicine Ingredients

radiopharmaceuticals
Telix Pharmaceuticals Limited, a clinical-stage biopharmaceutical company, has announced the acquisition of Belgium-based Advanced Nuclear Medicine Ingredients (ANMI).

Israeli alpha-radiation cancer therapy developer starts clinical trials in Italy

mri
Alpha Tau Medical has announced the initiation of two new clinical trials evaluating the efficacy of the Alpha DaRT) with two leading medical centers in Rome (Italy).

Novartis intends to acquire biopharmaceutical company Endocyte

novartis
Novartis announced that it has entered into an agreement and plan of merger with Endocyte, a US-based biopharmaceutical company focused on developing targeted therapeutics for cancer treatment.

Rusatom Healthcare and MedInvestGroup set up a production of radiopharmaceuticals

radiopharma
Rusatom Healthcare JSC (integrator of Rosatom State Corporation radiation technologies) and MedInvestGroup LLC, a part of the Pharmstandard group, signed a cooperation agreement.

VEB supported new radiopharmaceuticals production in Russia

radiopharmaceuticals
Russian "Bank for Development and Foreign Economic Affairs" opened financing for a project to organize the production of radiopharmaceuticals.

Rosatom suggests to develop Russian radiopharmaceutical based on Yttrium-90

rosatom
Specialists suggest developing the first Russian radiopharmaceutical based on the radioactive isotope Yttrium-90 for the treatment of cancer.

CivaTech Oncology developed novel bio-absorbable radiation treatment

radiopharmaceuticals
Physicians are now able to successfully implant a new bio-absorbable, internal radiation treatment known as CivaSheet® to treat a patient with recurrent lung cancer.

Isotopia and Bar-Ilan University intend to develop a new radioactive marker

radiopharmaceutical
The Israeli Isotopia Company, in collaboration with Prof. Rachela Popovtzer of Bar-Ilan University's Faculty of Engineering, is conducting a joint study to develop a radioactive marker for the detection of cancer.

IRM plans to launch manufacturing of its first radiopharmaceuticals in 2019

irm
A Nuclear Medicine Center may be soon established in the Ural region as a result of efforts by the specialists of the Institute of Reactor Materials (an enterprise of Scientific Division of Rosatom State Corporation).

Endocyte and ITM signed a long-term global supply agreement

radiopharmaceuticals
Endocyte and ITM Isotopen Technologien München AG (ITM) announced that ITM´s subsidiary and Endocyte have signed a long-term global supply agreement for the highly purified, no-carrier-added Lutetium-177 (177Lu) EndolucinBeta.

New cyclotron in St. Petersburg will help to develop a novel biomarker

radiopharmaceutical drug
Russia’s first new generation cyclotron (accelerator of particles) intended for manufacturing pharmaceuticals for cancer diagnosis was installed at Dr. Berezin Medical Institute (MIBS) in St. Petersburg.

Telix Pharmaceutical sets up research partnership with INSERM and ARRONAX

radiopharmaceuticals
Telix Pharmaceuticals announced a research partnership with the French National Institute of Health and Medical Research and the “Accelerator for Research in Radiochemistry and Oncology at Nantes Atlantic”.

Actinium Pharmaceuticals and Astellas will collaborate on a radiopharmaceutical

radiopharmaceuticals
Actinium Pharmaceuticals entered into a research and option agreement with Astellas Pharma to develop Actinium-225 Radio-Conjugates (ARCs) using its Actinium Warhead Enabling (AWE) Platform Technology.